Onco Wiki / Maladie

Lymphome classique de Hodgkin

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDDIS-CHL
TypeMaladie
Alias
Maladie de Hodgkin (sous-types NS/MC/LR/LD)cHLКласична лімфома Ходжкіна
Étatreviewed 2026-04-25 | pending_clinical_signoff
MaladiesAucune déclaration
SourcesSRC-NCCN-BCELL-2025

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Source YAML

icd_o_3_morphology9650/3
icd_10C81.9
who_classificationHodgkin lymphomas — Classical Hodgkin lymphoma per WHO 5th ed. (4 morphologic subtypes — nodular sclerosis, mixed cellularity, lymphocyte-rich, lymphocyte-depleted)

Capacités

Notes

Stage-driven 1L: early (I-II) → ABVD × 2-4 + ISRT (response-adapted per interim PET-CT Deauville score); advanced (III-IV) → ABVD × 6 OR A+AVD × 6 (ECHELON-1 — brentuximab replaces bleomycin, OS benefit). escBEACOPP for high-risk advanced (more European preference). Differential — mediastinal/hilar adenopathy: sarcoidosis (D86.0–D86.2) mimics cHL on CT and PET/CT (bilateral hilar uptake, mediastinal and subcarinal nodes). Discriminators: histology (Reed-Sternberg CD15+/CD30+ absent in sarcoid; non-caseating granuloma present), serum ACE, calcium, ophthalmology exam. Biopsy mandatory before chemotherapy; steroids before biopsy mask sarcoid granulomata and confound cHL histopathology.

Utilisé par

Pertinence thérapeutique

Algorithmes

Maladie

Indication

Questionnaires

Signal d’alerte

Sources